Compare · CORT vs LLY
CORT vs LLY
Side-by-side comparison of Corcept Therapeutics Incorporated (CORT) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CORT and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.07T, about 136.7x CORT ($7.80B).
- Over the past year, CORT is up 3.1% and LLY is up 46.4% - LLY leads by 43.3 points.
- CORT has been more active in the news (23 items in the past 4 weeks vs 16 for LLY).
- LLY has more recent analyst coverage (25 ratings vs 15 for CORT).
- Company
- Corcept Therapeutics Incorporated
- Eli Lilly and Company
- Price
- $72.77-2.84%
- $1132.80+0.65%
- Market cap
- $7.80B
- $1.07T
- 1M return
- +39.53%
- +14.77%
- 1Y return
- +3.15%
- +46.44%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 23
- 16
- Recent ratings
- 15
- 25
Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest CORT
- Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
- Chief Development Officer Guyer William exercised 20,000 shares at a strike of $21.65 and sold $1,412,000 worth of shares (20,000 units at $70.60) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Lyon Joseph Douglas was granted 1,074 shares and covered exercise/tax liability with 269 shares, increasing direct ownership by 13% to 7,035 units (SEC Form 4) (tax liability)
- Chief Development Officer Guyer William was granted 1,754 shares, increasing direct ownership by 79% to 3,985 units (SEC Form 4)
- Officer Maduck Sean exercised 25,000 shares at a strike of $8.27, sold $1,755,183 worth of shares (25,000 units at $70.21) as part of a pre-agreed trading plan, was granted 1,230 shares and covered exercise/tax liability with 452 shares, increasing direct ownership by 9% to 9,755 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Mokari Atabak exercised 40,000 shares at a strike of $19.26, sold $2,800,004 worth of shares (40,000 units at $70.00) as part of a pre-agreed trading plan, was granted 1,268 shares and covered exercise/tax liability with 395 shares, increasing direct ownership by 6% to 16,130 units (SEC Form 4) (tax withholding)
- Chief Business Officer Robb Gary Charles was granted 1,552 shares and covered exercise/tax liability with 358 shares, increasing direct ownership by 5% to 25,681 units (SEC Form 4) to satisfy tax liability
- SEC Form 8-K filed by Corcept Therapeutics Incorporated
- Chief Executive Officer Belanoff Joseph K gifted 300,000 shares, received a gift of 300,000 shares and sold $895,252 worth of shares (12,837 units at $69.74) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Lyon Joseph Douglas sold $325,000 worth of shares (5,000 units at $65.00), decreasing direct ownership by 45% to 6,230 units (SEC Form 4)
Latest LLY
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial